{"id":"NCT01029262","sponsor":"Celgene","briefTitle":"A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Compare The Efficacy And Safety of Lenalidomide (Revlimid®) Versus Placebo In Subjects With Transufsion-Dependent Anemia Due to IPSS Low Or Imtermidate-1 Risk Myelodysplastic Syndromes Without Deletion 5Q(31) And Unresponsive Or Refractory To Erthropoiesis-Stimulating Agents","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01-26","primaryCompletion":"2013-03-17","completion":"2018-05-09","firstPosted":"2009-12-09","resultsPosted":"2015-06-18","lastUpdate":"2019-06-25"},"enrollment":239,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"Lenalidomide","otherNames":["Revlimid","CC-5013"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Arm #1 - Lenalidomide plus placebo","type":"EXPERIMENTAL"},{"label":"Arm #2 - placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to investigate whether lenalidomide would reduce the number of red blood cell transfusions (RBC) needed in anemic (RBC transfusion-dependent) participants with low or intermediate-1 risk MDS without a deletion 5q chromosome abnormality. The study also investigated the safety of lenalidomide use in these participants. Two-thirds of the participants received oral lenalidomide and one-third of the participants received oral placebo.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC)","timeFrame":"From first dose of study drug until 28 days after the last dose, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.","effectByArm":[{"arm":"Placebo","deltaMin":2.5,"sd":null},{"arm":"Lenalidomide","deltaMin":26.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":14},"locations":{"siteCount":99,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","France","Germany","Israel","Italy","Japan","Poland","Portugal","Spain","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["27354480","32064987","29322849"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":79},"commonTop":["NEUTROPENIA","DIARRHOEA","THROMBOCYTOPENIA","ASTHENIA","OEDEMA PERIPHERAL"]}}